

Claims

1. (currently amended) A method of treating wounds in a patient which comprises treating the patient with an effective amount of 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one a ~~cGMP PDE5~~ inhibitor, or a pharmaceutical composition thereof, wherein the wound type is selected from: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.
2. (canceled)
3. (previously presented) A method or use as claimed in claim 1, wherein the inhibitor is administered orally or topically.
- 4 – 13 (canceled)